Johnson & Johnson
-
With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
-
FDA Calls for New Safety Warning for the Class of CAR T Cancer Therapies
Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
BioPharma, Devices & Diagnostics, Health Tech
7 JPM Announcements You Don’t Want to Miss
This year’s J.P. Morgan Healthcare Conference brought a bevy of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for seven of the event’s most notable announcements.
-
J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition
Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.
-
GSK Drug Pulled From Market Beats J&J Multiple Myeloma Med in Phase 3 Test
GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.
-
J&J’s Robotic Bronchoscopy System Could Help Physicians Detect Cancer Sooner, Research Finds
Johnson & Johnson released research this month showing that its system for robotic-assisted bronchoscopy helped physicians achieve an over 15% improvement in overall diagnostic yield compared to traditional bronchoscopy. This could mean that fewer patients will have to “wait and see” while their cancer potentially gets worse.
-
Pfizer Expands to Multiple Myeloma With FDA Approval for New Antibody Drug
Oncology is already a big piece of Pfizer’s drug lineup. The portfolio is expanding to multiple myeloma with FDA approval of Elrexfio, a bispecific antibody that targets the cancer protein BCMA.
-
FDA Approves J&J Combo Drug for Prostate Cancers With Certain Genetic Signature
Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.
-
J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug
Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
J&J Gets Foothold in Head & Neck Cancer With Deal for Nanobiotix’s Lead Program
Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.
-
Bausch + Lomb Continues Deal Streak With $106M Acquisition of J&J Eye Drops
Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J&J exits the consumer business while Bausch + Lomb expands its product portfolio with its second deal in as many weeks.
-
J&J Plans Phase 3 Trial to Keep Pace in the Chase for Oral Psoriasis Drugs
Johnson & Johnson’s oral psoriasis drug met the goals of a mid-stage clinical study, and the pharma giant now plans to advance the twice-daily pill to Phase 3 testing. J&J is one of several biopharmaceutical companies developing pill alternatives to biologic drugs that are injected or infused.
-
J&J Expands in Cancer, Paying $245M for Two Next-Generation Cell Therapies
Johnson & Johnson is acquiring rights to two next-generation cell therapies from Cellular Biomedicines, both potential treatments for diffuse large B-cell lymphoma. One therapy is already in the clinic while the other is on track to begin human testing this year.
-
J&J Portfolio Review Culls RSV Vaccine, Ending the Phase 3 Program
Johnson & Johnson’s pullback from RSV research thins the pack of companies aiming to develop a vaccine for the pathogen. GSK and Pfizer have vaccines under FDA review and a shot from Moderna could soon follow.
-
J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test
A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.